首页|期刊导航|中国实验方剂学杂志|加味半夏泻心汤的提取工艺优化和物质基础分析

加味半夏泻心汤的提取工艺优化和物质基础分析OA

Optimization of Extraction Process and Material Basis Analysis of Modified Banxia Xiexintang

中文摘要英文摘要

目的:基于药效学评价,结合G1-熵权法与Box-Behnken响应面法,优选并验证加味半夏泻心汤(MBXT)醇水双提的最佳提取工艺,并系统全面地解析该复方的化学药效物质基础,为该方的质量控制和工业化生产提供科学依据.方法:将大鼠随机分为空白组、模型组、二甲双胍组及MBXT全方水提组、水提醇沉组、醇水双提组.除空白组外,各组大鼠通过高脂饮食联合来曲唑诱导建立多囊卵巢综合征伴胰岛素抵抗(PCOS-IR)模型,采用酶联免疫吸附测定法(ELISA)生化检测试剂盒及HE染色比较血清性激素水平及卵巢病理形态,筛选提取工艺路线.在此基础上,采用G1-熵权法,基于盐酸小檗碱、黄芩苷的转移率与干膏得率构建综合评分,利用Box-Behnken响应面法优化提取工艺参数.最后,采用超高效液相色谱-四极杆-静电轨道阱质谱法(UPLC-Q-Orbitrap-MS)对最佳工艺样品进行化学成分定性分析.结果:药效学结果显示,与空白组比较,模型组大鼠血清睾酮(T)、黄体生成素(LH)水平显著升高,雌二醇(E2)、促卵泡生成素(FSH)显著降低(P<0.01),卵巢呈多囊样改变;与模型组比较,各给药组均能显著逆转性激素水平的变化,其中醇水双提组改善上述指标及病理形态效果最优,并进行后续工艺优化.优选的最佳醇水双提工艺为加12倍量70%乙醇提取2次,每次120 min;加12倍量水提取3次,每次90 min.验证试验结果显示,最佳工艺条件下盐酸小檗碱和黄芩苷平均转移率分别为76.05%和93.38%.MS分析共鉴定出377种化合物,包括黄酮类112种、萜类41种、有机酸类28种、香豆素类22种及生物碱类8种等,并解析了关键成分的裂解规律.结论:优选的醇水双提工艺稳定可行,能有效保留MBXT治疗PCOS-IR的药效物质基础,进一步明确了该复方的主要化学成分组成,可为其制剂的研发及质量控制提供科学依据.

Objective:To optimize and validate the optimal sequential alcohol-water extraction process of modified Banxia Xiexintang(MBXT)based on pharmacodynamic evaluation,combined with the G1-entropy weight method and Box-Behnken response surface methodology,and to systematically and comprehensively analyze the material basis of this formula,providing a scientific basis for its quality control and industrial production.Methods:Rats were randomly divided into the normal group,model group,metformin group,and MBXT water extraction,water extraction and ethanol precipitation,sequential ethanol-water extraction groups.Except for the normal group,a polycystic ovary syndrome with insulin resistance(PCOS-IR)model was established in all rats via a high-fat diet combined with letrozole induction.Enzyme-linked immunosorbent assay(ELISA)biochemical assay kits and hematoxylin-eosin(HE)staining were used to compare sex hormone levels in serum and ovarian histopathology,thereby screening extraction process routes.Based on this,a comprehensive score was constructed using the G1-entropy weight method based on the transfer rates of index components(berberine hydrochloride and baicalin)and the dry extract rate.Box-Behnken response surface methodology was then utilized to optimize the extraction process parameters.Finally,the chemical constituents of the sample from the optimal process were qualitatively analyzed by ultra-performance liquid chromatography-quadrupole-electrostatic field orbitrap mass spectrometry(UPLC-Q-Orbitrap-MS).Results:Pharmacodynamic findings revealed that compared with the normal group,serum testosterone(T)and luteinizing hormone(LH)levels were significantly elevated in the model group,while estradiol(E2)and follicle-stimulating hormone(FSH)levels were significantly decreased(P<0.01),with polycystic changes observed in ovarian tissues.Compared with the model group,all treatment groups significantly reversed the changes in sex hormone levels,with the sequential ethanol-water extraction group showing the optimal effect in improving the aforementioned indicators and pathological morphology,followed by subsequent process optimization.The optimized process involved adding 12 times the amount of 70%ethanol for extracting twice,each lasting 120 min,and adding 12 times the amount of water for extracting thrice,each lasting 90 min.Validation test results showed that under optimal process conditions,the average transfer rates of berberine hydrochloride and baicalin were 76.05%and 93.38%,respectively.MS analysis identified a total of 377 compounds,including 112 flavonoids,41 terpenoids,28 organic acids,22 coumarins,and 8 alkaloids,while elucidating the cleavage patterns of key components.Conclusion:The optimized sequential ethanol-water extraction process is stable and feasible,effectively preserving the material basis of MBXT for treating PCOS-IR.It further clarifies the main chemical composition of this formula,providing a scientific basis for the development and quality control of its preparations.

刘宇灵;汤如莹;郑冬雪;张琪苓;刘新敏;白栋汉;林龙飞

中国中医科学院中药研究所,北京,100700中国中医科学院中药研究所,北京,100700中国中医科学院广安门医院,北京 100053中国中医科学院中药研究所,北京,100700中国中医科学院广安门医院,北京 100053中国中医科学院中药研究所,北京,100700中国中医科学院中药研究所,北京,100700

医药卫生

多囊卵巢综合征伴胰岛素抵抗(PCOS-IR)药效学研究提取工艺Box-Behnken响应面法物质基础分析加味半夏泻心汤

polycystic ovary syndrome with insulin resistance(PCOS-IR)pharmacodynamic researchextraction processBox-Behnken response surface methodologymaterial basis analysismodified Banxia Xiexintang

《中国实验方剂学杂志》 2026 (7)

129-139,11

国家重点研发计划项目(2022YFC3501900)中央高水平中医医院临床研究和成果转化能力提升项目——医疗机构制剂研发与新药转化专项(HLCMHPP2023050)

10.13422/j.cnki.syfjx.20260165

评论